COVID-19

Members of the Vanderbilt Health team are evaluating the efficacy of the immunomodulatory drug baricitinib for treating the persistent neurological and cardiopulmonary symptoms of long COVID. (photo by Donn Jones)
February 6, 2026

Vanderbilt Health to lead expanded multisite study of immunomodulation in long COVID

The public health burden of long COVID is estimated to be the largest seen from an emerging disease in the past century, yet there remain no effective interventions.

By Jill Clendening
November 3, 2025

Prescribing with purpose

A Vanderbilt University Medical Center study finds unnecessary antibiotic prescriptions in hospitalized children and highlights opportunity for antibiotic stewardship.

By Chelsea N. Campbell
July 22, 2025

Study provides new data on COVID outcomes for cancer patients 

Death incidence was highest in patients with lymphoma, intermediate in patients with acute leukemia and lung cancer, and lowest in patients with other solid tumors or with blood cancers other than lymphoma.

By Tom Wilemon
June 30, 2025

Coronavirus pioneer Mark Denison bids farewell to VUMC colleagues after remarkable career

The discoveries about coronavirus biology that Denison and his colleagues made were foundational for the rapid validation of antiviral drugs and development of new vaccines that helped bring the COVID-19 pandemic under control.

By Bill Snyder
December 17, 2024

Immune-suppressing drug does not improve COVID-19 recovery: study

Previous studies suggested that fostamatinib may suppress inflammatory responses triggered by COVID-19 and mitigate ongoing lung injury, decreasing mortality and oxygen requirements.

By Bill Snyder
October 25, 2024

Asthma drug does not speed COVID-19 recovery: study

The study, a randomized and controlled clinical trial, tested the effectiveness of montelukast in 1,250 outpatients with acute post-COVID-19 symptoms.

By Bill Snyder and Shantell Kirkendoll
September 13, 2024

VUMC joins national effort to prevent another pandemic

Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.
By Bill Snyder
May 8, 2024

Supercomputing redesign of a COVID monoclonal antibody

The approach, which combines high-performance computing, simulation, machine learning and experimental validation, will help keep antibody drugs up to date in the future against highly variable viruses.
By Leigh MacMillan
May 7, 2024

A team approach to care 

LSU baseball fan sporting a new set of lungs after VUMC transplant
By Matt Batcheldor
March 5, 2024

CDC encourages additional COVID-19 vaccine dose for patients 65 and older

March 5, 2024

CDC changes community COVID-19 isolation guidance; does not change guidance for Vanderbilt Health employees, patients or facilities

February 22, 2024

NIH-funded trial to determine if immunomodulation can improve brain and cardiovascular dysfunction in Long COVID

Vanderbilt University Medical Center is working with scientists around the U.S. to launch the first Phase III, multicenter, placebo-controlled trial to determine the effect of immunomodulation on Long COVID.
By Nancy Humphrey
January 2, 2024

Team uses COVID-19 to test automated acute disease profiling

An automated solution for creating phenotyping algorithms, PheNorm, worked well to identify symptomatic COVID-19 cases in electronic health records, suggesting that automation could speed high-throughput phenotyping of acute disease.
By Paul Govern
1 2 3 … 38